A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection
Richard Elion(Gilead Sciences (United States)), Javier Szwarcberg(InterScience (United States)), Jean‐Michel Molina(Assistance Publique – Hôpitaux de Paris), Nicolas Margot(Gilead Sciences (United States)), Ya-Pei Liu(Gilead Sciences (United States)), Steven L. Chuck(Gilead Sciences (United States)), Franco Maggiolo(Ospedale Papa Giovanni XXIII), Brian Conway, Martin S. Rhee(Gilead Sciences (United States)), David A. Cooper(UNSW Sydney), Edmund Wilkins(North Manchester General Hospital), José Ramón Arribas(Hospital Universitario La Paz)
Cited by 41
Related Papers
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
|The Lancet|2011|2.1k
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
|New England Journal of Medicine|2006|886
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
|Gastroenterology|2006|882
Infections with<i>Cryptococcus neoformans</i>in the Acquired Immunodeficiency Syndrome
|New England Journal of Medicine|1989|801